Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR‑384/pleiotrophin axis

Yao,Yuanyuan; Rao,Chunhui; Zheng,Gang; Wang,Saisai

doi:10.3892/or.2019.7136

Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR‑384/pleiotrophin axis

Authors:
- Yuanyuan Yao
- Chunhui Rao
- Gang Zheng
- Saisai Wang
View Affiliations

Affiliations: Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Colorectal Surgery, Hangzhou Hospital of Traditional Chinese Medicine, Guangxing Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
Published online on: April 24, 2019 https://doi.org/10.3892/or.2019.7136
Pages: 131-141
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Luteolin (3,4,5,7‑tetrahydroxyflavone) is a natural flavonoid that has been found to exhibit anticancer properties in certain types of cancers. In the present study, the role of luteolin and its underlying mechanisms were explored in colorectal cancer (CRC) cells. First, the effects of luteolin on CRC cells proliferation, migration and invasion were examined by CCK‑8, wound healing and Transwell assays, respectively. It was demonstrated that luteolin had no effects on CRC cells proliferation while inhibited cells migration and invasion both in vitro and in vivo. Then, expression of pleiotrophin (PTN) and miR‑384 was detected in cells and CRC tissues by qPCR. Luteolin was found to upregulate miR‑384 and downregulate PTN expressions both in CRC cells and tissues. miR‑384 inhibition and PTN overexpression partially reversed the inhibition of HT‑29 cells migration and invasion induced by luteolin. Target analysis revealed that miR‑384 directly regulates PTN expression. The correlation analysis between PTN expression and clinical characteristics revealed that PTN expression was positively related to cancer progression. The present study demonstrated that luteolin exerts anticancer effects against CRC cells by modulating PTN via miR‑384 expression suggested that PTN may serve as a promising candidate for therapeutic applications in CRC treatment.

View Figures

View References

1	Peng M, Watanabe S, Chan KW, He Q, Zhao Y, Zhang Z, Lai X, Luo D, Vasudevan SG and Li G: Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin. Antiviral Res. 143:176–185. 2017. View Article : Google Scholar : PubMed/NCBI
2	Peng M, Swarbrick CMD, Chan KW, Luo D, Zhang W, Lai X, Li G and Vasudevan SG: Luteolin escape mutants of dengue virus map to prM and NS2B and reveal viral plasticity during maturation. Antiviral Res. 154:87–96. 2018. View Article : Google Scholar : PubMed/NCBI
3	Zhang H, Tan X, Yang D, Lu J, Liu B, Baiyun R and Zhang Z: Dietary luteolin attenuates chronic liver injury induced by mercuric chloride via the Nrf2/NF-κB/P53 signaling pathway in rats. Oncotarget. 8:40982–40993. 2017.PubMed/NCBI
4	Guo YF, Xu NN, Sun W, Zhao Y, Li CY and Guo MY: Luteolin reduces inflammation in Staphylococcus aureus-induced mastitis by inhibiting NF-κB activation and MMPs expression. Oncotarget. 8:28481–28493. 2017.PubMed/NCBI
5	Zang Y, Igarashi K and Li Y: Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-A^y mice. Biosci Biotechnol Biochem. 80:1580–1586. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhou Y, Ding BZ, Lin YP and Wang HB: MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene. 644:56–65. 2018. View Article : Google Scholar : PubMed/NCBI
7	Byun EB, Song HY, Mushtaq S, Kim HM, Kang JA, Yang MS, Sung NY, Jang BS and Byun EH: Gamma-irradiated luteolin inhibits 3-isobutyl-1-methylxanthine-induced melanogenesis through the regulation of CREB/MITF, PI3K/Akt, and ERK pathways in B16BL6 melanoma cells. J Med Food. 20:812–819. 2017. View Article : Google Scholar : PubMed/NCBI
8	Chen P, Zhang JY, Sha BB, Ma YE, Hu T, Ma YC, Sun H, Shi JX, Dong ZM and Li P: Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget. 8:27471–27480. 2017.PubMed/NCBI
9	Wang Q, Wang H, Jia Y, Pan H and Ding H: Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma. Cancer Chemother Pharmacol. 79:1031–1041. 2017. View Article : Google Scholar : PubMed/NCBI
10	Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F and Zhang Y: Luteolin promotes cell apoptosis by inducing autophagy in hepatocellular carcinoma. Cell Physiol Biochem. 43:1803–1812. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lim W, Yang C, Bazer FW and Song G: Luteolin inhibits proliferation and induces apoptosis of human placental choriocarcinoma cells by blocking the PI3K/AKT pathway and regulating sterol regulatory element binding protein activity. Biol Reprod. 95:822016. View Article : Google Scholar : PubMed/NCBI
12	Shen XF, Teng Y, Sha KH, Wang XY, Yang XL, Guo XJ, Ren LB, Wang XY, Li J and Huang N: Dietary flavonoid luteolin attenuates uropathogenic Escherichia. Coli invasion of the urinary bladder. Biofactors. 42:674–685. 2016. View Article : Google Scholar : PubMed/NCBI
13	Krifa M, Leloup L, Ghedira K, Mousli M and Chekir-Ghedira L: Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions. Nutr Cancer. 66:1220–1227. 2014. View Article : Google Scholar : PubMed/NCBI
14	Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett. 281:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
15	Pandurangan AK, Dharmalingam P, Sadagopan SK, Ramar M, Munusamy A and Ganapasam S: Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/β-catenin/GSK-3β signaling. J Environ Pathol Toxicol Oncol. 32:131–139. 2013. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Lang T, Jin B, Chen F, Zhang Y, Beuerman RW, Zhou L and Zhang Z: Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study. J Proteomics. 161:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
17	Manju V and Nalini N: Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem Funct. 25:189–194. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ashokkumar P and Sudhandiran G: Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother. 62:590–597. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chian S, Li YY, Wang XJ and Tang XW: Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac J Cancer Prev. 15:2911–2916. 2014. View Article : Google Scholar : PubMed/NCBI
20	Qu Q, Qu J, Guo Y, Zhou BT and Zhou HH: Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway. Anticancer Drugs. 25:1016–1027. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
22	Bracken CP, Scott HS and Goodall GJ: A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
23	Eichmuller SB, Osen W, Mandelboim O and Seliger B: Immune modulatory microRNAs involved in tumor attack and tumor immune escape. J Natl Cancer Inst. 109:2017. View Article : Google Scholar : PubMed/NCBI
24	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
25	Han K, Meng W, Zhang JJ, Zhou Y, Wang YL, Su Y, Lin SC, Gan ZH, Sun YN and Min DL: Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 9:3085–3094. 2016. View Article : Google Scholar : PubMed/NCBI
26	Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X and Wu MH: Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of microRNA-34a-5p. Int J Mol Sci. 19:E4472018. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wang YX, Chen YR, Liu SS, Ye YP, Jiao HL, Wang SY, Xiao ZY, Wei WT, Qiu JF, Liang L, et al: MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget. 7:84826–84838. 2016.PubMed/NCBI
29	Kang KA, Piao MJ, Ryu YS, Hyun YJ, Park JE, Shilnikova K, Zhen AX, Kang HK, Koh YS, Jeong YJ, et al: Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. Int J Oncol. 51:1169–1178. 2017. View Article : Google Scholar : PubMed/NCBI
30	Abdel Hadi L, Di Vito C, Marfia G, Ferraretto A, Tringali C, Viani P and Riboni L: Sphingosine kinase 2 and ceramide transport as key targets of the natural flavonoid luteolin to induce apoptosis in colon cancer cells. PLoS One. 10:e01433842015. View Article : Google Scholar : PubMed/NCBI
31	Muramatsu T: Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 132:359–371. 2002. View Article : Google Scholar : PubMed/NCBI
32	Yao J, Zhang LL, Huang XM, Li WY and Gao SG: Pleiotrophin and N-syndecan promote perineural invasion and tumor progression in an orthotopic mouse model of pancreatic cancer. World J Gastroenterol. 23:3907–3914. 2017. View Article : Google Scholar : PubMed/NCBI
33	Bai PS, Xia N, Sun H and Kong Y: Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma. J Cell Mol Med. 21:3023–3043. 2017. View Article : Google Scholar : PubMed/NCBI
34	Ma J, Kong Y, Nan H, Qu S, Fu X, Jiang L, Wang W, Guo H, Zhao S, He J and Nan K: Pleiotrophin as a potential biomarker in breast cancer patients. Clin Chim Acta. 466:6–12. 2017. View Article : Google Scholar : PubMed/NCBI
35	Jee YH, Sadowski SM, Celi FS, Xi L, Raffeld M, Sacks DB, Remaley AT, Wellstein A, Kebebew E and Baron J: Increased pleiotrophin concentrations in papillary thyroid cancer. PLoS One. 11:e01493832016. View Article : Google Scholar : PubMed/NCBI
36	Chang Y, Zuka M, Perez-Pinera P, Astudillo A, Mortimer J, Berenson JR and Deuel TF: Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc Natl Acad Sci USA. 104:10888–10893. 2007. View Article : Google Scholar : PubMed/NCBI
37	Lampropoulou E, Logoviti I, Koutsioumpa M, Hatziapostolou M, Polytarchou C, Skandalis SS, Hellman U, Fousteris M, Nikolaropoulos S, Choleva E, et al: Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration. Sci Rep. 8:58932018. View Article : Google Scholar : PubMed/NCBI
38	Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS, Zhang L, Chen L, Lan X, Zhang XC, et al: Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 8:150802017. View Article : Google Scholar : PubMed/NCBI
39	Yamakawa T, Kurosawa N, Kadomatsu K, Matsui T, Itoh K, Maeda N, Noda M and Muramatsu T: Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers. Cancer Lett. 135:91–96. 1999. View Article : Google Scholar : PubMed/NCBI
40	Kong Y, Bai PS, Nan KJ, Sun H, Chen NZ and Qi XG: Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int J Colorectal Dis. 27:287–298. 2012. View Article : Google Scholar : PubMed/NCBI
41	Sun H, He L, Ma L, Lu T, Wei J, Xie K and Wang X: LncRNA CRNDE promotes cell proliferation, invasion and migration by competitively binding miR-384 in papillary thyroid cancer. Oncotarget. 8:110552–110565. 2017. View Article : Google Scholar : PubMed/NCBI
42	Wang G, Pan J, Zhang L, Wei Y and Wang C: Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Cell Prolif. 50:2017. View Article : Google Scholar :
43	Fan N, Zhang J, Cheng C, Zhang X, Feng J and Kong R: MicroRNA-384 represses the growth and invasion of non-small-cell lung cancer by targeting astrocyte elevated gene-1/Wnt signaling. Biomed Pharmacother. 95:1331–1337. 2017. View Article : Google Scholar : PubMed/NCBI
44	Song H, Rao Y, Zhang G and Kong X: MicroRNA-384 inhibits the growth and invasion of renal cell carcinoma cells by targeting astrocyte elevated gene 1. Oncol Res. 26:457–466. 2018. View Article : Google Scholar : PubMed/NCBI
45	Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C and Liu Y: CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 axis. Mol Ther. 24:1199–1215. 2016. View Article : Google Scholar : PubMed/NCBI
46	Chen Z, Yu C, Zhan L, Pan Y, Chen L and Sun C: LncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384. Am J Cancer Res. 6:2299–2309. 2016.PubMed/NCBI